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ABSTRACT 
Background: EBV is a lymphotropic herpesvirus and the causative agent of infectious 
mononucleosis. EBV is highly prevalent and has been linked to several malignancies. 
The virus is generally transferred by oral secretions and it persists as a latent infection in 
human B-cells. However, it can be also transmitted through blood transfusions and organ 
transplantations. The goal of this study was to (i) estimate the rate of infection of EBV 
in Qatar in healthy individuals, using serological testing, and viral load quantification, to  
(ii) study the correlation of EBV with demographic markers, and to (iii) study the 
molecular similarity of EBV isolates, using phylogenetic genotyping. Materials and 
methods: For estimating EBV seroprevalence, qualitative ELISA kits for detecting the 
following EBV antibodies were used: EBV viral capsid antigen (VCA) IgG & IgM, EBV 
nuclear antigen (EBNA) IgG & IgM, and early antigen (EA-D) IgG. To study the EBV 
viremia rate, DNA extracted from the buffy coat was subjected for viral detection and 
quantification using RT-PCR. For genotyping, nested PCR targeting the EBNA2 gene 
was used. And for further sub genotyping, the highly variable LMP-1 gene was 
amplified, cloned, sequenced and used for phylogenetic analysis. Results: Out of 673 
analyzed samples (223 Qataris, 450 non-Qatari residents), 659 (97.9%) were EBV 
seropositive with different infection stages. Interestingly, 14 (2.1%) tested negative for all 
anti-EBV antibodies indicating no prior exposure to EBV. EBV DNA was detected in 
354/673 (52.6%). Both EBV seroprevalence and viremia rate increased significantly with 
age. Genotyping for 51 randomly selected positive DNA samples showed that Genotype 
1 was predominating, found in 36/51 (72.5%), while genotype 2 was found in 12 (23.5%) 
samples. Mixed infection was found in 2 (3.9%) samples. Surprisingly, Sub genotyping 
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for 30 samples revealed that all tested clones (n=119) have the South Eastern Asia 1 
(SEA1) strain. 30-bp and 69 bp deletions in the LMP-1 were also found in 10% and 
13.3% samples, respectively. Conclusion: This is the first study investigating the 
seroprevalence, the viremia rate, and the molecular epidemiology of EBV among blood 
donors in Qatar. Hence, it should provide the epidemiologists, blood banks’ personnel, 
researchers and clinicians with EBV prevalence estimates and molecular epidemiology of 
EBV as a highly prevalent transfusion transmissible oncovirus. 
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1- INTRODUCTION 
Epstein bar virus (EBV), or human herpesvirus 4, is a lymphotropic herpesvirus 
and the causative agent of infectious mononucleosis. It was first discovered in cells 
isolated from African Burkitt’s lymphoma, then it was recognized that it is highly 
prevalent worldwide (1). Like other herpesviruses, EBV has a latency phase, following 
the primary infection, it enters into the circulating B lymphocyte and persists for life in a 
latent state (2). It’s estimated that more than 90% of world’s populations is EBV-
seropositive (3).  Usually, the primary infection occurs in childhood, and it is 
asymptomatic, but when infection occurs in adults it leads to infectious mononucleosis 
(IM) (4). This virus has also been linked to wide range of diseases including multiple 
sclerosis (MS), and malignancies, such as gastric carcinoma, Hodgkin’s lymphoma and 
nasopharyngeal carcinoma (NPC) (3-6).  
EBV genome is composed of a linear, double stranded DNA with a size of 172 
kilobase pairs (kbp) that encodes for more than 85 genes (4, 5). Most of the proteins 
encoded by the EBV genome are involved in nucleotide metabolism, to maintain the 
replication of the viral DNA (5, 7). In latency, only small number of viral genes are 
expressed, which are six EBV nuclear proteins: EBNA-1, EBNA-2, EBNA-3A, EBNA-
3B, EBNA-3C, EBNA-LP, and three latent membrane proteins: LMP-1, LMP-2A, LMP-
2B (4). 
There are two main EBV genotypes, Type 1 and Type 2, or Type A and B, 
respectively  distinguished based on the differences in EBNA-2 gene, since the 
divergence in EBNA-2 reveals only 54% homology between the two types (8). EBV 
types 1 and 2 can further be subdivided into different virus strains (9). Most of 
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investigations of the genetic variability of EBV strains were based on studying the LMP-
1 gene, because it showed to have a greater degree of polymorphism than most of the 
EBV genes. LMP-1 is a 356-amino acid protein that plays an important role in signal 
transduction and cell survival. Variants in LMP-1 were classified into 7 main groups: 
B95-8, Alaskan, China 1, China 2, Med+, Med- and NC (3, 5, 10). However, new strains 
were reported from different origins. In Thailand, two other new variants were found 
which were named : Southeastern Asia 1 (SEA1), and Southeastern Asia 2 (SEA2). CAO 
variant was also isolated from nasopharyngeal carcinoma patients (11, 12) Interestingly, 
it was reported that multiple EBV variants can be detected within one individual. These 
variants were also correlated with cancer progression. A variant with 30 bp deletion, was 
isolated from NPC tumor, and showed to have a higher transforming activity than the 
typical LMP-1 (13).  
EBV is transmitted through the oral rout, which is the primary rout of 
transmission; however, it has been reported that transfusion and organ transplantation are 
also routes of EBV spread (14-16). Although there are efforts from blood banking 
organizations to minimize the risk of transfusion transmission, through screening for 
numerous infectious pathogens, there it is still a concern regarding transmission of 
untested pathogens, such as EBV (17). Blood banks rely on the leukoreduction procedure 
to ensure the safety of blood products, but although leukoreduction procedure can 
pointedly reduce the number of EBV genome, it was found that EBV can be still detected 
in leukoreduced products. In conclusion,  leukoreduction doesn’t completely eliminate 
the EBV carrying cells, and this signals a potential risk for blood products recipients, 
especially if they are immunocompromised (17, 18).   
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Several studies were conducted to investigate the presence of EBV genome in 
healthy blood donors. Many studies also have shown the geographic distribution of EBV 
strain variants among healthy infected carriers. However, to the best of our knowledge, 
no study have been conducted in Qatar concerning EBV detection and genotyping in 
neither cancer patients nor healthy donors. Accordingly, the aim of this study was to 
answer preliminary questions about EBV in Qatar; through studying the rate of infection 
of EBV in the country, the demographic distribution of the virus in relation to gender, 
age, and ethnicity in Qatar, and how genetically similar tested strains are to previously 
reported EBV strains. This work aims to help the blood banks in Qatar by providing them 
with  preliminary data about EBV viremia, as a blood transmitted oncovirus, hence, 
improving the health standard of the community by providing a better standard of health 
services.  
 
Hypothesis 
Qatar is Multinational country, with a mixed population. We hypothesize that:  Multiple 
or new EBV variants are expected to be found in healthy blood donors in Qatar. 
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2- LITERATURE REVIEW 
2.1 EBV History and Discovery  
The discovery of EBV started with the identification of a novel lymphoma affecting 
young children in central Africa, which was first reported by Denis Burkitt in 1958 (19-21). 
The unique geographical pattern of the disease distribution, which was related to 
environmental conditions, where equatorial rainy areas were more affected, drew the 
attention towards the hypothesis that an infectious agent could be involved in the 
transmission process (22, 23). In 1964, Epstein-Barr virus was first identified by Epstein, 
Achong, and Barr in cultured Burkitt’s lymphoma cells. Using electron micrographs, they 
showed a herpesvirus like particles with unique antibody reactivity, not similar to any other 
known herpesviruses. Then, in 1965, it was confirmed that a new human virus was officially 
identified which belongs to the herpes family, and named Epstein-Barr virus (23).  
 
2.2 EBV Structure and Genome 
The EBV virion structure is similar to other herpesviruses. It consists of a toroid 
shaped protein core wrapped with the viral DNA inside an icosahedral capsid of 162 
capsomers, a viral tegument containing a protein that lines the space between the 
nucleocapsid and the outer envelope. Different glycoprotein spikes are inserted into the 
viral envelop (5, 24). 
EBV genome is composed of a linear, double stranded DNA with a relatively 
large genome size of ~ 172 kilobase pairs (kbp) that encodes for more than 85 genes (4, 
5). In order to have the highest coding capacity, the viral genome is divided into short and 
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long unique sequence domains by a series of around 540 bp terminal direct repeats and 
around 3.1 kbp large internal repeats (7, 25). These repetitions serve as an indicator to 
determine whether the source of EBV in the infected cells came from the same progenitor 
cell. That is, when EBV infects a cell, the viral DNA persists as a circular episome, that 
when passes to the future generations, it retains the same number of terminal repeats 
during the latent phase of infection (5). The nomenclature of the EBV open reading 
frames (ORFs) was established according to the BamHI-restriction fragments, where they 
were found and ordered in descending order from A to Z, based on the fragment sizes. 
The fragments were also divided into latent or lyric genes (5, 24). 
Most of the proteins encoded by EBV genome are involved in nucleotide 
metabolism (to maintain the replication of the viral DNA) and to build the structural 
compartments of the virus such as nucleocapsid, tegument proteins, and the envelope (7). 
Additionally, EBV genome consists of several latent genes that are non-translated during 
the lytic phase and number of latency associated RNA genes that are expressed during 
latency (5, 7). During latent EBV infection, the viral genome persists for life-long in 
multiple circular episomes inside the infected cell nucleus. To maintain this episome like 
plasmids during cell division, two components are needed: a cis-acting DNA segment 
(oriP), and a trans-acting nuclear protein (26). In latency, only few viral genes are 
expressed, which includes the six EBV nuclear proteins: EBNA-1, EBNA-2, EBNA-3A, 
EBNA-3B, EBNA-3C, EBNA-LP, plus three latent membrane proteins: LMP-1, LMP-
2A, LMP-2B (4). Furthermore, although EBV DNA usually persists in the form of 
episome, it was found that EBV DNA can integrate into the cell chromosomal DNA, and 
persist as integrated DNA as well (27).  
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2.3 EBV Types and Strain Variation  
It has long been known that there are two different EBV genotypes: Type 1 and 
Type 2, also known as Type A and B, respectively (25). These two types were 
distinguished based on the differences in EBNA-2 gene, since EBNA-2 clearly classifies 
Type 1 and Type 2, where the rest of the EBV genes differ only by less than 5% in their 
sequence (3, 5). EBNA-3 gene family show variations between EBV types, but with less 
degree of sequence difference than EBNA-2 gene (3). The divergence in EBNA-2 reveals 
only 54% homology between the two types, facilitating the distinction between each 
EBV type (8). Interestingly, it was found that EBV types noticeably differ in their 
transformation abilities, for instance, Type 1 transforms B lymphocytes more willingly 
than Type 2 in vitro, and when a recombinant Type 2 virus acquired Type 1 EBNA-2A 
gene, it gained the transforming ability of Type 1 virus (28).  In this study, the EBV were 
typed by nested PCR using different sets of primers that either recognize type 1 or 2.  
EBV types 1 and 2 can further be subtyped into different EBV strains (9). The 
genetic variability between EBV strain is thought to occur due to the nature of the EBV 
life cycle within the lymphocytes. For instance, when the EBV infected lymphocyte 
passes through the germinal center of the lymph node, which is considered as a highly 
mutagenic environment, increased rate of mutations could occur, , and thus, EBV also 
can induce errors during replication, creating more genetic variability between 
individuals (29). There are many studies in the literature that have focused on 
investigating the genetic variability of EBV strains and tried to correlate this variability to 
the geographic areas and to the disease outcomes. In these studies, genes which were 
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identified to have an important role in EBV viral life cycle were sequenced such as 
BZLF1, EBNA-1, EBNA-2, EBNA-3A, -3B, and -3C, LMP-1, and LMP-2a (4).  
Among the aforementioned genes, most of the recent investigations on EBV strain 
variation were based on studying the LMP-1 gene sequence, because it has showed to 
have a greater degree of polymorphism than most of EBV genes between different strains 
(3). LMP-1 is a 356-amino acid protein, which consists of a short cytoplasmic N-
terminus, six membrane spanning domains, and a long cytoplasmic C- terminal domain 
(30). The C-terminal domains (CTAR1, 2, and 3) of LMP-1 play an important role in 
signal transduction through mimicking the CD40-mediated signaling, and as a result, they 
work as homologous to the TNF-receptor family in the B lymphocytes and epithelial cells 
(5). Moreover, they regulate the NF-κB and cell survival in various pathways. Therefore 
when mutated, sequence variation can affect cell process directly as it interferes with 
major signaling pathways (3). It is well known now, that LMP-1 is essential in the 
transformation of B lymphocytes into lymphoblastoid cell line, and it has the ability to 
block apoptosis as a result of upregulating different anti-apoptotic proteins such as A20 
and Bcl-2, and inhibiting the p53-mediated apoptosis (5). 
Based on the LMP-1 sequence variation,  EBV strains were classified into 7 main 
groups (variants) relative to the wild type strain B95-8. Naming of these variants reflects 
their geographic origin or from where they were driven: Alaskan (Ala), China (Ch1) and 
(Ch2), Mediterranean (Med+) and (Med-) and North Carolina (NC) (3, 10). However, 
new strains were reported from different origins. In Thailand, two other new variants 
were found which were named : Southeastern Asia 1 (SEA1), and Southeastern Asia 2 
(SEA2). CAO variant was also isolated from nasopharyngeal carcinoma patients (11, 12) 
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Multiple EBV variants can be detected within one individual, as a patient can be 
infected with more than one type (9). There are evidences of specific multiple LMP-1 
variants found in people infected with infectious mononucleosis, as well as in other EBV 
associated malignancies such as Hodgkin Lymphoma and Nasopharyngeal carcinoma 
(NPC). In HIV patients, multiple EBV strains can be present (3). Interest in LMP-1 
variants was increased, when findings correlated LMP-1 variants with specific cancers. 
For example, a variant with 30 bp deletion was detected frequently in NPC patients and 
this variant showed higher transforming activity than the typical LMP-1 (13). 
Furthermore, a 69 bp deletion variant has also been reported in Burkitt’s lymphoma and 
in a lesser rate with NPC. Further, the 69 deletion was also correlated with decreased cell 
AP1 transcription factor activation (3, 31). Several reports also investigated the presence 
of LMP-1 variants among healthy carriers (9, 32, 33). A recent study compared the 
prevalence of EBV genotypes and del-LMP-1 among Polish, Taiwanese and Arabic 
healthy individuals revealed that 62.5% Taiwanese and 55.6% Polish had 30-bp deletion 
in the LMP-1 gene, however, Arabs didn’t have this deletion (33). Another study 
investigated the frequency of 30 bp deletion in EBV healthy carriers from Argentina and 
found that it is present in 28% of these healthy people (32) . However, it is still not 
known how many EBV variants can be found in one individual, and whether the immune 
system of a previously infected individual provides protection against new multiple 
variants (29).  
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2.4 EBV Viral Tropism (activation) 
Many  studies have been conducted to investigate the EBV host cell interactions, 
and the latency associated with EBV infection in  different cell types and various medical 
conditions. These studies have investigated virus cell interaction in different infection 
conditions, such as in malignancies, lymphoproliferative disease in transplantation and in 
the normal B lymphocytes  during infectious mononucleosis (34). In normal hosts, B 
lymphocytes and epithelial cells are the cellular targets for EBV primary infection. 
However, EBV can infect wide range of non-B lymphocytes and it critically affects the 
development and pathogenesis of EBV related diseases (35). Early studies reported the 
presence and replication of EBV viral particles in the oropharyngeal epithelial cells of 
patients with acute infectious mononucleosis (36, 37), and in epithelial cells of HIV 
patients suffering from oral hairy leukoplakia (38). More recent studies showed that the 
tonsil epithelium of asymptomatic patients has the ability to carry EBV infection, which 
is a part of the viral life cycle (39). Furthermore, EBV has the ability to infect T 
lymphocytes, plasma cells, NK cells, monocytes, follicular dendritic cells squamous, 
myoepithelial and glandular epithelial cells, and also smooth muscle cells (40-44).   
Despite the wide range of suspected cell types that can be involved in EBV 
infection, it is believed that B lymphocytes have a critical role in the viral life cycle, as 
agammaglobulinemia patients, who have a genetic mutations that leads to the absence of 
mature B lymphocytes, are not affected with EBV (45). Primary B lymphocytes can be 
easily infected with EBV, because B lymphocytes possess a major receptor molecule of 
the virus called cellular complement receptor type 2 (CR2 or CD21), which binds to EBV 
glycoprotein gp350/220 (46). On the other hand, the interaction of EBV with epithelial 
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cells is less understood. It was believed that epithelial cells acquire the infection through 
transfer from EBV-coated B lymphocytes (34). In vitro studies showed that a low rate of 
infection was achieved when epithelial cells were exposed to cell free virus preparations, 
while a quantifiable level of infection was reached when epithelial cells were cultured 
with EBV infected B lymphocytes. This prompts the idea of the importance of B 
lymphocytes in the initiation of infection, as EBV must go through an initial cycle of 
replication in a primary B lymphocyte before it reaches epithelial cells (47). EBV also 
might enter the epithelium through the surface of resting B lymphocyte. B Lymphocyte 
can act as a transfer vehicle, to transfer EBV infection to CD21 negative epithelial cells 
after EBV binds to its surface (47). However, it is still in doubt whether B lymphocytes 
or epithelial cells. are the primary target of EBV spread (7).  
 
2.5 EBV Viral Life Cycle 
Usually EBV spreads through saliva, and upon entry of the virus, it enters the 
epithelium of the tonsils, where it starts the lytic phase of infection that involves virus 
replication (5). Infected naive B lymphocytes become activated lymphoblasts and migrate 
to the lymph node follicle to initiate a reaction in the germinal center of the follicle using 
the “latency III” program, where all latent growth proteins are expressed and adversely 
regulate EBV growth. This includes EBV nuclear antigens (EBNA-1, -2, -3, -3A, -3B, -
3C, and -LP), and latent membrane proteins LMPs (LMP-1, -2A, and -2B) (5, 46). Type 
II latency program then is initiated in which only EBNA1, the EBERs, the BARTs, LMP-
1 and LMP-2A are expressed (46) and survival signals will be provided to cells to move 
out of the germinal center as memory B lymphocytes (5). “Latency 0” begins in the 
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memory B lymphocytes, and it is characterized by turning off all viral proteins expression 
(5). If EBNA-1 gene only is expressed when these memory B lymphocytes divide, then 
this is called “latency type I” (26, 48). Infected memory B lymphocytes can also migrate 
back to the tonsils, where they can elicit more viral replication that can spread and infect 
other B lymphocytes as well (2). In the primary infection, T lymphocytes are responsible 
for eliminating the newly infected cells and to control the infection, however, during 
latency, EBV is hidden from the immune system as it remains silent in the resting 
memory B lymphocytes with no expression of any viral protein (5, 49).  
Viral reactivation can happen occasionally in latently infected memory B 
lymphocytes and leads to a new viral cycle, where it replicates, infects new cells, and 
sheds in the saliva (46). Under healthy conditions, immunocompetent individuals can 
have EBV reactivation with no specific symptoms due to the infection control by the 
cytotoxic T lymphocytes (50). However, EBV reactivation can be life threatening in 
patients under immunosuppression and can lead to severe EBV related pathologies such 
as post-transplant lymphoproliferative disorders (PTLDs) (50). There are several 
described causes of EBV reactivation, such as the presence of foreign antigen that leads 
to memory B lymphocytes division, which in turn can induce viral reactivation and 
replication (51). This means that any new infection can lead to EBV reactivation (5). For 
instance, malaria infection have been linked to EBV reactivation, as P. falciparum 
antigens can directly trigger EBV reactivation, and therefore can increase the risk of 
developing Burkitt’s lymphoma in malaria endemic areas (52). The cystein-rich inter-
domain region 1α (CIDR1α) in the P. falciparum membrane protein 1, was found to 
activate the memory B lymphocytes where EBV resides (52). Another cause is 
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immunodeficiency and immunosuppression, due to altered immune system. In this case, 
uncontrolled reactivation of EBV may occur and can lead to various lymphoproliferative 
diseases (50). Other factors, such as inflammation and chemical agents or drugs, have 
been also linked to EBV reactivation from latently infected cells (5).  
 
2.6 EBV Prevalence and Transmission  
In healthy individuals EBV is highly prevalent, as it affects more than 90% of 
individuals around the world (53). The age of primary infection was found to vary 
according to socioeconomic factors that are reflected by crowdedness and low sanitation 
(5). EBV seroconversion occurrence has two patterns. In developed counties with high 
hygiene standards, EBV seroconversion peaks in children between 2 to 4 years and also 
in 14 to 18 years, and it increases with age, ranging from 0 to 70% at childhood and 
reaching to more 90% in adulthood (17). In contrast, countries with less hygiene 
standards, EBV is usually acquired in early childhood, and almost all children in those 
developing countries are seropositive by the age of 6 years (54).  
EBV types occur worldwide but they differ in their geographic distribution. EBV 
type 1 is prevalent in Europe, America, China, and South Asia, while EBV type 2 is less 
prevalent in these populations and it is more observed in African and Papua New 
Guinean populations, where it shares an equal distribution with type 1 (5, 55). 
Immunocompromised patients are more susceptible to acquire both types (5). However, 
heathy individuals (with less frequency) as well can have mixed infection with both type 
1 and 2 (9). In my study, I found that EBV type 1 is more prevalent than type 2, yet, 
mixed infection was also detected. 
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The main route of EBV transmission is the oral route, as it is generally 
transmitted through saliva that contains infected epithelial cells (54). Also, it can spread 
through blood, blood transfusion and organ transplantations (14, 16, 17, 56). Infected 
epithelial cells can also be found in the uterine cervix or in the semen, suggesting the 
possibility of EBV spread through sexual contact (54). Kissing, sharing personal 
objectives such as toothbrushes, eating utensils, or sharing food and drinks with an 
infected individual can all lead to EBV spread (56).  
 
2.7 EBV in Blood Transfusion and Organ Transplantation  
It has long been known that blood transfusions and organ transplantations can be 
routes for EBV transmission, as reported in 1969 by Gerber et al. (14). In this study, the 
authors showed that patients receiving donor blood during an open heart operation 
acquired EBV, indicating the possibility of EBV transmission by blood transfusion. 
Furthermore, early studies revealed that EBV transmission can be through organ 
transplantation, where patients developed infectious mononucleosis after transplantation 
(15, 16). Reports showed that a healthy EBV seropositive individual carry around 0.1 to 
50 EBV infected B lymphocytes per 1,000,000 peripheral blood mononuclear cells 
(MNCs). Therefore it’s possible that EBV can be transmitted through white blood cells of 
the blood (17, 57).  
Multiple studied were conducted to estimate the prevalence of EBV DNA in the 
blood of healthy blood donors., Results revealed that EBV DNA detection in blood 
donors varies from low to high rates. In US, a study showed that 72% of a 100 randomly 
selected blood donors had a detectable EBV DNA, suggesting that the potential for 
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transfusion-mediated transmission EBV is high (58). In Japan, randomly selected blood 
donors were tested for the presence of EBV DNA and results showed that EBV DNA was 
detected in 39.5% of the donors (59). Another recent study in Burkina Faso showed a 
lower level of EBV rate among blood donors, as it was detected in only 5.1% of the 
donors (60). In this study, 52.6% of blood donors have detectable EBV DNA in their 
peripheral blood. 
EBV has been linked to the development of post-transplant lymphoproliferative 
disorders (PTLD’s), which are a group of heterogeneous diseases that develop in 
immunocompromised patients after receiving a solid organ or hematopoietic stem cell 
transplant (61). The incidence of lymphoproliferative disorders increases with solid organ 
and bone marrow transplantations (62, 63). These disorders develope as a result of 
immunosuppression, and they vary from benign slow polyclonal proliferations to overtly 
malignant monoclonal proliferations of lymphocytes and plasma cells (61, 64). PTLD 
was first reported in 1968 in two renal transplantation recipients, and it was linked to the 
immunosuppressive therapy that was administered to the patients (65). Mortality from 
PTLDs is high with no progress in the outcomes over the years. In fact, the highest risk of 
developing PTLDs was in the first year after initiation of transplantations (66). The 
World Health Organization (WHO) classifies PTLDs to: (i) early lesions of polyclonal or 
oligoclonal lymphoid proliferations that are mainly derived from EBV infection; and (ii) 
late monoclonal lymphoproliferative diseases that are not necessarily associated with 
EBV, including polymorphic and monomorphic PTLDs, which also can be subdivided 
into Burkitt's lymphoma, Burkitt's-like lymphoma, diffuse large B-cell lymphoma and 
Classical Hodgkin Lymphoma (67).  
  
 
15 
 
It has been known that oncogenic herpesviruses like EBV and HHV-8 are 
involved in the development and pathogenesis of PTLDs, because these viruses have the 
ability to directly infect and transform B lymphocytes (67). Indeed, EBV was found to be 
present in up to 2/3 of PTLD cases (61). A higher risk to develop PLTD is found in EBV 
negative than in EBV positive recipients regardless the status of the donor, but the 
highest risk is when the recipient is EBV negative, and the donor is EBV positive (68).  
In EBV infection, when the viral genome presents in an episomal form in the 
latent period of infection, few latent genes are expressed in different latency programs 
and these genes code for proteins that are found to have a direct oncogenic effect (5). 
When immunosuppression is severe, EBV positive cells express latency type III program, 
and transformed B lymphocytes grow continuously in the absence of effective EBV 
specific cytotoxic T cells (2). Genes that are expressed include EBNA-3 group (EBNA-
3A, -3B, and -3C), which are extremely oncogenic (5). Increased EBV viral load, and 
decreased cytotoxic T cells is strongly linked to the development of PTLD (61). When 
autologous EBV specific cytotoxic T cells were used to treat PTLDs, EBV viral load was 
controlled and tumor size was reduced (67), which confirms the strong association of 
EBV to this disease. 
The efforts to prevent transmission of EBV from EBV positive donors is based on 
the process of leukoreduction, which was introduced in 1999, and aims to remove the 
white blood cells from various blood products (69). Qu et al. concluded in a study of 
leukoreduction efficacy, that EBV PCR negative blood products after leukoreduction, are 
expected to have a very low probability of transmissible EBV, and the risk is highly 
reduced (70). However, in another recent published in the international journal of 
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transfusion medicine, a group of scientist found that EBV was detected in one platelets 
bag after leukoreduction (18). This data shows a clear evidence that leukoreduction 
doesn’t rule out the possibility of EBV transmission, and leukoreduced blood products 
can harbor EBV. Consequently, there is a potential risk in immunocompromised patients 
who are more vulnerable to EBV infection, and patients who receive large volumes of 
blood (18).  
Although the process of leukoreduction decreases the viral copies present in the 
WBCs, it is important to draw the attention that the risk of EBV transmission, or other 
certain blood transfusion viruses, is not completely eliminated, and transmission is not 
100% prevented by leukoreduction (17). For instance, a study has shown that CMV 
seronegative blood units can enhance the safety of blood transfusion more than 
leukoreduced blood products in at risk patients like organ transplantation and 
immunosuppressed patients. Thus, leukoreduced blood products are not equal to 
seronegative blood products with regard to safety, and this might be applied for EBV as 
well (17, 71).  
 
2.8 Detection of EBV 
The clinical presentation of EBV infection usually overlap with other acute viral 
syndromes caused by other viruses such as hepatitis viruses and cytomegalovirus (CMV), 
which can lead to similar symptoms (72). This emphasizes the importance of having 
reliable laboratory diagnostic tools that help in the differential diagnosis. Diagnostic 
schemes of EBV differ according to the patient’s immune condition, because the 
importance and urgency of therapeutic intervention differ between immunocompromised 
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and immunocompetent individuals. Testing for anti-EBV antibodies was and still the 
most widely used laboratory assay to evaluate the infection. This includes nonspecific 
tests such as hetetophile antibodies detection (mono spot test), and a wide range of EBV 
specific serological assays such as: ELISA, EIA, IFA, chemoluminescence, immunoblot, 
and IgG avidity. In addition to the serological testing, molecular assays for nuclear acid 
detection such as in PCR, in situ hybridization and in situ PCR are also important (73). 
Other diagnostic tools also have been used in detection of EBV-associated tumors such as 
immunhistochemistry and immunocytology (73, 74). 
 
2.8.1 EBV Serological Testing: 
Serological testing is based on the detection of EBV antibodies in the patient’s 
serum. Although the serology for EBV diagnosis shows a high degree of variability, it’s 
still preferred and commonly used, as it provides a reasonable criteria to identify the 
patient’s infection status (73). EBV genome codes for different structural and 
nonstructural genes, some of these genes are used in the serological diagnosis, as the 
humoral response produces antibodies against the product of these genes. This includes: 
the gene that codes for the viral capsid antigens (VCAs), the early antigens (EAs), as well 
as the genes that code for Epstein Barr nuclear antigens (EBNAs) (72, 73). Heterophile 
test is also one of the commonly used tests to help in the clinical diagnosis. This test is 
based on detecting heterophile antibodies which are antibodies that agglutinate 
erythrocytes from animal source, and are mainly linked to mononucleosis caused by EBV 
infection or infrequently by other diseases (75). This test is easy to perform, inexpensive 
and commercially available, but it lacks specificity, as false positive results were reported 
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in other non EBV conditions such as in autoimmune diseases and cancer (76). Moreover, 
this assay shows low sensitivity with high false negative results when used for children 
younger than two years old, as they might lack specific EBV antibodies (75, 77). In 
immunocompetent individuals, usually at least three serological parameters are needed to 
detect EBV antibodies: VCA-IgG, VCA- IgM, and EBNA-1 IgG (78). Detection of IgG 
antibodies to EBV early antigen EA can also be done and helps in differentiation of the 
EBV diseases status (73, 75) (Figure 1) 
Viral capsid antigen (VCA) is a complex of 7 structural proteins and 
glycoproteins, and it is synthesized in the lytic cycle of EBV replication (79). 
Serodiagnosis of VCA is based on the detection of antibodies against the two 
recombinant viral capsid antigens: the N- terminal of full length p23 and the carboxy half 
of p18 (80). These two proteins were joined in vitro by autologous gene fusion in 1999, 
which then established the base for developing novel EBV ELISAs (80, 81). Detection of 
VCA antibodies involves the two immunoglobulin classes IgG and IgM. The humoral 
response to the VCA complex is typically found early at the onset of clinical symptoms 
(76) . In a study investigating EBV status in college students, VCA-IgM was detected by 
enzyme immunoassay 8 days earlier than the onset of symptoms (76). VCA- IgM is 
produced transitionally and used as an indicative of recent primary infection. That is, 
VCA-IgM is no more detected after convalescence, and generally it doesn’t occur another 
time in life (73). Although VCA IgM appears early and helps in the diagnosis of acute 
EBV infection, there are some limitations that interfere with the accurate interpretation of 
the results. For example, some children and adults might have negative VCA-IgM in 
primary acute infection (75), and EBV-IgM cross-reactivity with other antigenically 
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related infections especially CMV infection was also reported (82, 83). VCA- IgG is 
found in acute, convalescence or past infections, as it starts to appear at the same time as 
VCA-IgM (73, 75, 80). Antibodies against the p18 components develop after p23 
antibodies, and then persists for life as an indication of EBV exposure (76). Measuring 
VCA- IgG antibodies is found to be best single test to indicate a previous EBV infection 
as all patients with infectious mononucleosis produce IgG antibodies to VCA (84).  
EBV nuclear antigen (EBNA) is composed of 6 proteins (EBNA-1, -3, -3A, 3B, 
3C and LP) (2) . EBNA-1 is expressed in all EBV infected cells, and IgG against this 
protein is a late marker of EBV infection (84).  EBNA-1 IgG antibodies appear late, 3 to 
6 months after the time of disease, then they decline but continue to present in a 
detectable level for life Thus, detection of EBNA-1 antibodies indicates past or 
recovering EBV infection (5, 84). However, VCA- IgG indicates past infection more 
accurately than EBNA- IgG, because EBNA- IgG is never developed in around 5%- 10% 
of EBV infected healthy individuals, and this percentage is higher in 
immunocompromised patients (76, 85). Usually antibodies to EBNA are tested by 
standard immunofluorescent assays and enzyme immunoassays. However, EBNA 
enzyme immunoassays may give false positive results (56, 75, 78). The IgM class of 
EBNA-1 in not usually measured, but when detected, it indicates a recent primary 
infection, however, it may persists for several months after the primary infection and it 
can reappear again in reactivation (75). EBNA-1 IgM has cross reactivity with other 
viruses such as CMV and Parvovirus B19, and it may show false negative results (86, 
87).  
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Early antigen (EA), is a complex of nonstructural proteins that are expressed by 
EBV infected cells in the lytic phase. It is composed of two components: diffused EA-D 
and restricted EA-R (88) . IgG antibodies against EA are detected transiently in up to 3 
months or more during infection mononucleosis (85). Usually the humoral response is 
against the D component, however, children undergoing silent EBV seroconversion 
might also produce antibodies to the R component (75, 89). High levels of EA-R 
antibodies have been detected in Burkitt’s lymphoma (75), and can also be indicative of 
reactivation of a latent EBV infection (90). In contrast, high titers of EA-D were found to 
be produced in nasopharyngeal carcinoma patients (91). Hence, detection of only EA 
antibodies can’t serve as a definitive diagnosis to identify the EBV condition, because 
high titers are found in different diseases, and in healthy individuals as well (92). 
Usually, EA antibodies appear in the acute phase and then declines to undetectable levels, 
but studies showed that only 60% to 85% of acute infection patients have EA positive 
results (73, 76) and 20% to 30% of healthy individuals with past EBV infection have 
detectable levels of EA antibodies (73).  Because of these reasons, the diagnostic value of 
these antibodies is still debatable (75). Nevertheless, combining EA antibodies testing 
with other diagnostic tools can be useful in the diagnosis.  
In general, EBV infection in immunocompetent patients is detected and classified 
using the previously mentioned antibodies in patients’ sera, but when results are 
uninterpretable or can’t clearly distinguish the stage of infection, other assays can be 
done to confirm the suspected diagnosis, such as western blot, immunoblot, and more 
commonly, the IgG avidity testing (76, 93). 
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Figure 1. A scheme of serological response to EBV infection. VCA IgM is detected in the 
active phase of infection, and then declines in convalescence. VCA IgG increases at the 
same time of VCA IgM but it remains positive for life indicating past infection. EBNA 
antibodies are detectable late in the phase of infection and also remain positive. EA 
antibodies to the class R or D increase in the acute phase on infection and decline after 
convalescence. Adapted from Johnson DH, 1995. 
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IgG Avidity Assay:  
Due to the high variability and cross reactivity in EBV serological responses, 
mainly with the VCA antibodies, more parameters are occasionally needed for the 
confirmation of infection condition. IgG avidity assay is usually used in combination 
with other serologic markers. It is based on the principle that during the acute phase of 
infection, the binding strength of EBV IgG antibodies to their target antigens is not as 
high as the antibodies binding strength after finishing the acute infection, as the 
antibodies undergo maturation (75, 94). Treating low avidity IgG antibodies with urea or 
chaotropic reagent leads to antibodies disassociation. Consequently, the difference in the 
antibodies amount before and after urea treatment is evaluated to determine the avidity 
strength which in turn represents the stage of infection and distinguish acute from past 
infection (76, 95). This method was found to be a reliable tool in EBV primary infection 
confirmation in patients with undetectable VCA-IgM, and in the differential diagnosis as 
well (93, 95).  
 
2.8.2 Molecular Assays  
Various molecular techniques have been developed and applied to detect EBV 
DNA and to quantify the viral load (40, 96-98). In situ hybridization, RNA and protein 
based assays, detection of EBV DNA in blood samples by quantitative real time PCR 
(qRT-PCR), Southern blotting and Dot blotting have all been used in the diagnosis and 
monitoring of primary EBV infection, reactivation, and in EBV related diseases (40, 99). 
These methods aid in the diagnosis, but due to the lack of standardization, the difference 
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in sensitivity and specificity from laboratory to laboratory should be always considered 
(75).  
There are many studies that have shown the importance of using qRT-PCR as a 
sensitive and reliable method and a complementary tool to other serologic markers, in 
particular, for diagnosis of EBV primary (acute) infection and EBV silent reactivation 
(50, 77, 100, 101). More importantly, this method is very crucial and widely used in 
monitoring the immune status for immunocompromised patients and in patients at risk of 
developing EBV-related diseases (102-104). However, the threshold value in which 
medical intervention is required, the units of measurement, and the best specimen to be 
used for DNA testing are still questionable and not standardized (75). Moreover, there is 
still no consensus on the ideal method for performing qRT-PCR for EBV detection and 
quantification, and this increases the variability between laboratories and between studies 
(40). Different detection methods are available commercially, some commercial primers 
and probes target include: LMP-2 gene, BHRF-1 (a transmembrane protein), BKRF1 
(EBNA-1 gene), BNRF1 (a major tegument protein), BXLF1 (thymidine kinase), BZLF1 
(ZEBRA) or BALF5 (viral DNA polymerase) (40, 75). The unit of measurement also 
varies; it can be reported as copies per DNA concentration as copies per microgram of 
DNA, or copies per milliliter, copies per 100,000 white blood cells, and copies per 
positive cell (40, 75, 105). Samples that were used qRT-PCR assays are various, 
including: serum, whole blood, tissue biopsy, and peripheral blood mononuclear cells 
(PMNCs). Although there is still much debate concerning these issues, but in general, the 
best specimen to use is based on the patient’s condition and the stage of the disease. 
Studies of EBV life cycle have showed that the production of EBV virions during the 
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acute phase of infection and the degradation of EBV DNA by apoptotic cells, both lead to 
the spread of virions and free or degraded EBV in the peripheral blood of the patient. 
Therefore, this allows for EBV DNA detection in patients’ peripheral blood (99, 106, 
107). In latent phase of infection, transformed B lymphocytes also travel to the blood 
(75). Consequently, EBV DNA in acute infection can be detected in the serum or in the 
unfractionated blood, as well as in the PMNCs.  
EBV DNA in acutely infected patients can be detected within two weeks of the 
onset of symptoms and it reaches its peak during this time (75). Then, after the initiation 
of immune response, the viral load starts to decrease rapidly to low or even undetectable 
levels in the plasma or serum (100), but decreases slowly in the cellular portion of blood, 
where it remains latent in the memory cells for long time, thus it can be detected if the 
sample was PMNCs (40, 108). However, it is important to consider the individual 
differences in EBV kinetics between patients as the viral load might take up to one year 
to reach a stable low level in some individuals according to immune status and the 
patient’s condition (40, 109). Studies showed that healthy individuals carry a stable 
number of EBV infected cells (82). In a healthy carrier, latently infected memory B 
lymphocytes harbor EBV genome, approximately, per 1 million leukocyte, there are 1-50 
copies of EBV DNA, while in serum or plasma EBV DNA is almost below the limit of 
detection (40) for the same individual. Therefore, the ability to detect EBV DNA in 
serum might serve as useful indicator for EBV primary infection or reactivation. Patients 
with active infection or with EBV related cancers have been found to have higher viral 
load in their cell free blood (40).  
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EBV DNA detection in patient’s serum can be useful especially in the early stages 
of the acute infection, and it was reported that it is more sensitive than serology and IgG 
avidity testing (100). However, it’s not necessary to be performed for immunocompetent 
patients, as serology is sufficient unless a result was indeterminate and an additional test 
was needed (110), or when EBV infection is strongly suspected with negative serology 
results (111). In EBV-associated diseases, the sample of choice differs based on the type 
of disease, for example, serum can be useful in detecting EBV DNA in Hodgkin’s 
lymphoma patients as the biology of the disease includes migration of episomal or 
apoptotic cells derived EBV DNA to the bloodstream, therefore , plasma or serum 
samples are desirable for EBV quantification (99). Similarly, in nasopharyngeal 
carcinoma, cancer cells proliferate in the tissue and uncommonly migrate to the 
peripheral blood, but cell free EBV DNA can be detected in the peripheral blood using a 
serum or plasma sample (99). In contrast, in PTLD, the disease biology involves blast B 
lymphocytes migration to the bloodstream, accordingly, using a PMNC specimen in 
preferable (99). Furthermore, it was found that the viral load correlates with the severity 
of the disease in EBV associated malignancies and lymphoproliferative diseases and can 
be used as a prognostic marker (108, 112).  
In conclusion, qRT-PCR is an important diagnostic tool especially in 
immunocompromised patients, where serology results may be confusing and unclear due 
to the incomplete humoral response. Furthermore, measuring the viral load by qRT-PCR 
is considered the best test to diagnose, monitor and anticipate the risk of developing EBV 
related disease in these patients (76, 113).  
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3- METHODOLOGY 
 
3.1 Sample Collection and Ethical Compliance 
Whole blood samples were collected in EDTA tubes from healthy donors at the 
Blood Donor Unit at Hamad Medical Corporation over a period of one year (Sep 2014 – 
Sep 2015). Blood samples were handled and stored following standard safety procedures 
and guideline. This study was approved by the Institutional Review Board (IRB) of Qatar 
University: (QU-IRB 518-EA/15). The study doesn’t include any harm to the 
participants.  Participants' rights were not harmed, because blood samples obtained from 
the blood bank were anonymous. The only information obtained were those related to 
nationality, sex, and age. All participants’ data was kept confidential.  
 
3.2 Sample Size 
Upon literature review, no specific information or estimates on EBV viremia rates 
or genotypes in Qatar were found. As this is the first study of its kind to be conducted in 
Qatar and, hence, due to non-availability of precise information related to primary 
outcome no formal sample size calculation is feasible for the present study. The total 
number of blood samples that were collected were 673 , 223 (33%) from Qatari donors 
and 450 (67%) from donors of other nationalities.   
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3.3 Ani-EBV Antibodies Testing 
3.3.1 Qualitative ELISA Testing of Anti- EBV Antibodies 
For the seroprevalence study, ELISA kits (Diagnostic Automation, USA) were 
used to screen plasma samples for the presence of EBV antibodies. A panel test was 
performed; this included screening antibodies for: viral capsid antigen (VCA) [both 
VCA- IgG (Catalog # 1405-2), and VCA- IgM (Catalog # 140692)], Epstein Barr nuclear 
antigen -1 (EBNA-1), [both EBNA-IgG (Catalog # 1425-1), and EBNA-IgM (Catalog # 
1426-1)], and EBV early antigen (EA)-IgG (Catalog # 1415-11).  
All ELISA assays were based on the same principle. In each kit, purified EBV 
antigens were coated on the surface of polystyrene microwells to bind to the specific 
complementary antibodies, if present in the tested sample, forming antigen-antibody 
complexes. Excess antibodies were then removed by washing. After washing, anti-human 
IgG conjugated with horseradish peroxidase was added, which will bind to the antibody-
antigen complexes. A second washing was then performed to remove excess conjugate, 
followed by adding of a substrate (Chromogen solution, tetramethylbenzidine TMB). At 
the end, the reaction was stopped by sulfuric acid, and then the optical density was read at 
450 nm wavelength against a reference of 620 nm wavelength using ELISA reader 
(BioTek, Epoch2, USA). Controls were included in each assay. Samples were considered 
positive if their values were above the cut-off value, while considered negative if they 
gave values lower than the cut-off. Samples with OD values in the equivocal range were 
retested, if they remained borderline, they were reported negative. Manufacture’s 
instructions regarding cut-off calculation, sample handling, and storage were accurately 
followed.  
  
 
28 
 
3.4. PMNCs Separation 
Ficoll-Paque PLUS (GE Healthcare Life Sciences, USA) was used for the 
isolation of lymphocytes from blood samples collected in EDTA tubes as per 
manufacturer’s instructions. Briefly, 1x Hank’s balanced salt solution (Life Technologies, 
USA) was used for 1:1 dilution of the blood samples and the diluted blood was layered 
on the Ficoll-Paque PLUS solution. After centrifugation, blood cells differentially 
migrated, resulting in the formation of different layers containing different cell types 
(Figure 2). The layer in the bottom contained aggregated erythrocytes, and the buffy coat 
containing polymorphonuclear cells (PMNCs), including lymphocytes, were at the 
interface between Ficoll reagent and the plasma. Plasma was discarded and PMNCs were 
collected in a separate tube. Finally, PMNCs were subjected to short washing steps using 
a balanced salt solution to remove any platelets, Ficoll-Paque PLUS and remaining 
plasma. Isolated PMNC were stored at -20 
o
C until performing DNA extraction  
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Figure 2. Ficoll separation of PMNCs. After centrifugation, blood cells differentially 
migrate, resulting in the formation of different layers containing different cell types . 
PBMCs are found in the interphase between the upper plasma layer and the ficll lower 
layer. . Adapted from Lin et al.,2014, Nature Protocols. 
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3.5 DNA Extraction 
DNA was extracted from PMNCs (buffy coat samples) as per manufacturer’s 
instruction of the  DNA extraction kit (Catalog # 51106, Qiagen, Germany). The 
concentration and the purity of all extracted DNA were measured using NanoQuant 
microplate reader (Infinite pro200, Tecan, Switzerland). Extracted DNA samples were 
then stored at -20 
o
C for further testing.  
 
3.6 EBV DNA Detection by Real Time PCR  
Detection and copy number quantification of EBV DNA in all extracted samples 
were performed using a real-time PCR detection and quantification kit  (Catalog # V48-
100FRT, Sacace, Italy) as per manufacturer’s instructions. The principle of the detection 
in this kit is based on using a real time amplification with fluorescent reporter dye probes 
specific for EBV. This kit is also provided with an indigenous internal control (IC), that 
amplifies β-globine gene, which allows for controlling the PCR amplification step, and 
insures the adequacy of sample preparation, materials, and storage conditions. In this kit, 
DNA samples were amplified using specific primers and polymerase (TaqF). The 
amplified DNA products were then detected using fluorescent dyes that are attached to 
oligonucleotide probes, which bind specifically to the DNA amplified product in the 
thermocycling step. QuantStudio™ 6 Flex Real-Time PCR instrument (Applied 
Biosystems, USA) was used for detection of the fluorescent dyes. Calibrators were used 
to construct the standard curve that was used to quantify EBV copies in the tested 
samples. The reaction was considered valid only if quantity of IC was more than 2000 
copies per reaction, and no amplification is detected in the negative control.  
  
 
31 
 
3.7 EBV Genotyping by Nested PCR of the EBNA-2 Gene 
EBV genotyping was performed using nested PCR of the EBNA2 gene, which is 
the target gene permitting genotype classification (8).  Briefly, in the first round of 
amplification, primers E2p1 and E2p2 were used to amplify a fragment of 596 bp 
covering almost the entire EBNA2 gene (E2p1: 5’-AGGGATGCCTGGACACAAGA-3’ 
and E2p2: 5’-TGGTGCTGCTGGTGGTGGCAA T-3’). In the second round of 
amplification, primers Ap1 and Ap2 (Ap1: 5’- TCTTGATAGGGATCCGCTAGGATA-
3’; Ap2: 5’-ACCGTGGTTCTGGACTATCT-GGATC-3’), were used to amplify a 497 
bp fragment which identify the EBV type-1 EBNA2 gene product, whereas primers Bp1 
and Bp2 (Bp1:5’-CATGGTAGCCTTAGGACATA-3’; Bp2:5’-
AGACTTAGTTGATGCCCTAG-3’) amplified a 150 bp fragment that characterize EBV 
type-2 EBNA2 gene product. PCR reaction was prepared in 0.2 ml microcentrifuge tubes. 
In a final mixture volume of 50 µl using HotStarTaq DNA Polymerase kit (Catalog # 
203203, Qiagen, Germany). Reaction mix contained 0.25 µl of HotStarTaq DNA 
Polymerase, 10 µl of 5x Q-Solution, 5 µl  of 10x PCR buffer which already contains 
15mM MgCl2, all from Qiagen kit, and 1 µl of 10mM dNTP's (Catalog # N0447S, New 
England Biolabs, USA). Additionally, 1 µl of 10µM/ µL of the above mentioned primers.  
For the first round of PCR using E2p1 and E2p2 primers, amplification conditions were 
as follows: after an initial heat activation step of 15 min at 95 
o
C, 40 cycles of 
amplification were performed: denaturation for 5 min. at 95 
o
C, annealing for 1 min. at 58 
o
C,  and extension for 1 min. at 72 
o
C, followed by a final extension step of 10 min. at 72 
o
C. For the second round of PCR, the same amplification conditions were used except for 
the  annealing temperature:  63 
o
C for Ap1 and Ap2 primers, and 53
 o
C for Bp1 and Bp2 
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primers. Afterwards, amplification products were visualized on 2% agarose gel by 
electrophoresis. In all experiments, a negative control (sterile H2O instead of DNA) and a 
positive control (previous positive sample) were used. 
 
3.8 EBV Sub Genotyping by Sequencing of LMP-1 gene  
 
3.8.1 Nested PCR of LMP-1 gene 
For the same genotyped samples, EBV subtyping was performed using LMP-1 
gene, which has a high degree of polymorphism and allows for further subgenotype 
identification (3). Starting with nested PCR of LMP-1 gene, the first round of 
amplification, primers A1 and A2 were used to amplify a fragment of 602 bp covering 
the C-terminus of LMP-1 gene (A1: 5’-AGTCATAGTAGCTTAGCTGAA-3’; A2 5’-
CCATGGACAACGACACAGT -3’). In the second round of amplification, primers B1 
and B2 aimed at amplifying a 587 bp fragment (B1: 5’-
AGTCATAGTAGCTTAGCTGAA-3’ ; B2: 5-AGTCATAGTAGCTTAGCTGAA-3’). 
Were used. PCR reaction was prepared in 0.2 ml microcentrifuge tubes to a final mixture 
volume of 50 µl using  HotStarTaq DNA Polymerase kit (Catalog # 203203, Qiagen, 
Germany). Reaction mix contained 0.25 µl of HotStarTaq DNA Polymerase, 10 µl of 5x 
Q-Solution, 5 µl  of 10x PCR buffer which already contains 15mM MgCl2 , all from 
Qiagen kit, and 1 µl of 10mM dNTP's (Catalog # N0447S, New England Biolabs, USA). 
Additionally, 1 µl of 20µM/ µL of the above mentioned primers was used, Amplification 
conditions were as follows: Starting with an initial heat activation step of 15 min at 95 
o
C, 40 cycles of amplification were performed in both round of PCR amplifications: 5 
  
 
33 
 
min. at 95 
o
C, 1 min. at 53 
o
C and 1 min. at 72 
o
C, followed by a final extension step of 
10 min. at 72 
o
C. Afterwards, amplification products were visualized and analyzed using 
2% agarose by gel electrophoresis. In each experiment, a negative control (sterile water 
instead of DNA) and positive control (previous positive sample) were used.  
 
3.8.2 Cloning  
 LMP-1 PCR products from 50 randomly selected samples were cloned, sequenced 
and compared to previous sequences deposited in GenBank and used for phylogenetic 
analysis. The PCR products (587 bp) of the randomly piched samples were purified using 
PCR purification kit (Qiagen; Germeny). Afterwards, these PCR purified samples were 
exposed to TA-cloning and ligation into pDrive cloning plasmid using the QIAGEN® 
PCR Cloning kit, all following the manufacturers' instructions (Figure 3). Three µL of the 
ligated plasmids were then transformed by electroporation into 50 µL home-made E. coli 
DH5α electrocompetent cells (Invitrogen, USA). Transformed cell were then resuscitated 
for 30 min in 300 µL SOC broth (Invitrogen) at 37 
o
C with shaking. SOC bacterial 
suspensions were then spread on LB medium containing 100 µg/mL ampicillin (Sigma, 
USA). Following an incubation period for 24 h, several distinct colonies from each 
culture plate were randomly picked. Then, each colony was subcultured in LB containing 
100 μg/ml ampicillin. After 24 hours incubation with shaking,  plasmids were purified 
using a QIAprep® Spin Miniprep Kit (Catalog # 231122, Qiagen, Germeny).  
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Figure 3. Cloning of the LMP-1 PCR product into pDrive cloning vector. Adapted from 
(Qiagen cloning kit insert sheet) 
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3.8.3 Phylogenetic Analysis 
Prior to sequencing, amplicons were examined for the presence of the cloned PCR 
products using restriction digestion with EcoRI enzyme. EcoRI restriction enzyme 
(Catalog # R0101S, New England Biolabs, USA), and 10X EcoRI buffer (Catalog# 
B0101S, New England Biolabs, USA) were used. A mix of 1 µL of EcoRI enzyme, 5 µL 
of 1X EcoRI buffer, and 4 µL of Plasmid DNA was prepared and incubated for at least 4 
hours at 37 
o
C. The amount of DNA in the reaction was increased or decreased based on 
the concentration. Digested samples were after that analyzed on 2% agarose gel by 
electrophoresis. Plasmids harboring the cloned fragment showed the presence of 587 bp 
band and a thicker large plasmid band.  
Sequencing was performed using a forward primer T7 and a reverse primer Sp6, 
using the ABI 3730XL sequencer in a sequencing facility. MEGA, version 6.0 freeware 
and CLC Main Workbench version 6.0.2. (CLC; Aarhus, Denmark) was used to do 
sequence alignments, and to construct phylogenetic and molecular evolutionary analyses. 
Moreover, to assess the degree of similarity between any two sequences, pair-wise 
distance differences analysis was used. For sequence homology comparison, reference 
sequences representing reported EBV strains were used. Sequences were aligned and 
phylogenetic tree was generated using the neighbor joining method.  
 
3.9 Statistical Analysis 
For determining the significance relation between variable ratios , chi-square test 
was used. For the correlation between EBV serology and real time PCR results, Kruskal 
Wallis test and Mann–Whitney U test were used. Results were considered statistically 
  
 
36 
 
significant when the calculated p-value < 0.05. The statistical software SPSS.23 was used 
for data analysis. GraphPad Prism 7.00 software was also used for statistic tests and 
constructing figures.  
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4- RESULTS 
4.1 Seroprevalence of EBV among Healthy Blood Donors in Qatar  
General Characteristics of studied population: A total number of 673 blood donor 
samples were used in the present study. From the total tested samples, 659 (97.9%) were 
males, whereas 14 (2.1%) were females. The number of Qatari individuals was 223 
(33.1%), and the non- Qatari residents 450 (66.9%). The age of the participant was 
ranged  between 19 and 68 years, with a mean age of 37 years (Table 1, Figures 4, 5, 6).   
For determining the seroprevalence of EBV in healthy blood donors in Qatar, all 
(673) plasma samples were tested for the presence of any of the following anti-EBV 
antibodies: VCA- IgG, VCA- IgM, EBNA1-IgG, EBNA-1 IgM, EA-IgG. We found that, 
97.9% (659/673) of the tested samples were seropositive for at least one of the 
aforementioned anti-EBV antibodies, indicating a prior exposure to EBV (Table 2, 
Figure7). For the EBNA-1 IgG 616 (91.5%) tested positive, while for the IgM class 
against EBNA 59 (8.8%) were positive. Seroprevalence of EA-IgG was 10.5% detected 
in 71 of the tested samples. VCA- IgG was positive in 659 (97.9%), while 12 (1.8%) 
were seropositive for VCA-IgM (Table 3, Figure 8). 
Serology patterns were classified into six possible EBV infection stages: Early 
infection, active infection, recent active infection, past infection, reactivation, and no 
infection. Out of the 659 seropositive individuals, 579 (86%) were positive for VCA-IgG 
and EBNA-IgG, or positive for VCA- IgG only, indicating past infection. Suspected viral 
reactivation was detected in 65 (9.7%) of samples, suggested by the positive results for 
VCA-IgG, EBNA-IgG, and EA-IgG. Moreover, 6 (0.89%) donors had a serologic profile 
that is suggestive of active infection as they tested positive for VCA-IgG, and EA-IgG, 
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with or without the presence of VCA-IgM. Recent active infection was suspected when 
VCA-IgM, VCA-IgG and EBNA-IgG test positive, which was detected in 5 (0.74%) 
samples. Further, 4 (0.6%) tested positive for VCA-IgM and VCA-IgG, suggesting early 
phase of EBV infection. Interestingly, 14 (2.1%) donors tested negative for all anti-EBV 
antibodies, indicating no previous or current infection (Table 4, Figure 9) 
 
4.2 Association of EBV Seroprevalence with Age, Gender, and Nationality  
In order to know whether there is an association between EBV seroprevalence and 
gender, age, and geographic origin of the participants, statistical analysis was performed. 
With regard to gender, although all females were EBV seropositive (100%), compared to 
the males (97.7%) positive, yet, this result doesn’t show a statistical significance 
(p=0.58), may be due to  the large difference in sample size between males (n=659) and 
females (n=14)  (Table 2). 
Qatar is a multinational country, with mixed ethnic population. Hence, we wanted 
to investigate EBV frequency among Qataris and non-Qatari resident, and further, among 
the six major nationalities that constitute the majority of our studied population. No 
significance was found in the EBV seroprevalence between Qataris and non- Qataris 
(p=0.84). Out of 233 Qatari donors, 218 (97.8%) were seropositive, and out of 450 
donors from other nationalities, 441 (98%) were seropositive. Further analysis was done 
among six major nationalities: Qatar (n=223), Syria (n=95), Egypt (n=92), 
Jordan/Palestine (n=61), India (n=59), Pakistan (n=20). Egyptians and Pakistanis had the 
highest rate of EBV seroprevalence (100%) in both countries, followed by Indian 
(98.3%), Syrian (96.8%), Qatari (97.8), and Jordanian/Palestinian nationalities (95.1%). 
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There was no statistical significance in EBV seroprevalence, or the stage of infection 
between the major nationalities of the studied population (p>0.05) (Table 4 and 5). 
Generally, because  EBV seroconversion is age oriented (57), thus, the association 
between age of participants and EBV seroprevalence was investigated in this study . We 
found that the infection rate increased significantly with age (p= 0.03), from 96% in 
individuals less than 30 years old, to 100% in people more than 40 years old. All 
individuals older than 40 years (n=233) were EBV seropositive (Table 4 , Figure 10). 
 
4.3 EBV Viremia Rate among Healthy Blood Donors  
A total of 673 DNA extracted samples were tested for the presence of EBV DNA, 
and for quantification of the viral load using qRT-PCR. EBV DNA was detected in 354 
(52.6%) of the samples. No significant association was found in viremia rate between 
males (52.8%) and females (42.9%), or between Qataris (55.2%) and non-Qataris 
(51.1%), or among major nationality groups. However, in regard to age, there was a 
significant association of viremia rate between age groups (p-value = 0.009), as viremia 
rate increased with age (Table 3). The lowest viremia rate was detected in the age group 
of people less than 30 years (44.8%), whereas the highest rate was exhibited by people 
aged 51 and older (67%) (Table 6 and 7). 
EBV viral load was calculated in copies per reaction, and copies per one 
microgram of extracted DNA. Viral load in the positive samples was ranged from 0.24 
copies/µg of DNA to 873.24 copies/µg, with a mean of 27.89 copies/µg. 
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4.4 Correlation between Serology and Real Time PCR findings 
For the total 673 tested samples, the correlation of serological testing by ELISA, 
and the EBV DNA detection by real time PCR was investigated. All EBV seronegative 
donors who had negative ELISA results for the five EBV antibodies, showed 
undetectable EBV DNA in their blood 14/14 (100%). Moreover, all donors with a 
antibodies profile suggesting EBV active infection had amplifiable EBV DNA 6/6 
(100%).  However, 3 out of 4 donors that were classified with an early EBV infection had 
positive EBV PCR (75%). For EBV recent active infection category, 2 out of 5 (40%) 
only showed detectable EBV DNA by PCR. And in EBV reactivation, 39 samples out of 
65 (60%) were EBV PCR positive. Last, 36/65 (52.6%) of individuals with EBV past 
infection had detectable levels of EBV DNA in their blood (Table 8,  Figure 11). 
The correlation between EBV viral load with the stage of infection was 
investigated. There was no significant difference in the viral load between different EBV 
stages (p>0.05) (Figure 12).  
 
4.5 EBV Genotypes among Blood Donors   
A total of 51 randomly selected samples from different nationalities were 
genotyped, using primers that amplify the EBNA2 gene. After the first round of PCR, all 
EBV positive samples produced a 597 bp fragment of the EBNA2 gene (Figure 13). 
Then, EBV type specific primers were used to distinguish between type 1, and 
type 2. EBV type 1 was characterized by an amplicon of 479 bp in length when using AP 
primers, while EBV type 2 was identified by a PCR product of 150 bp using BP primers 
(see materials and methods page 31). In samples with mixed EBV infection, both sets of 
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primers AP and BP positively amplified a 479 bp and 150 bp fragments respectively 
(Figure 14 and 15).  
Results of EBV genotyping showed that EBV type 1 is predominant. Out of the 
51 genotyped samples, there were 37 (72.5%) donors infected with EBV type 1, 12 
(23.5%) with type 2, and 2 (3.9%) with a mixed infection of both EBV genotypes. No 
significant association was found between EBV types and nationalities (p>0.05), and 
EBV type 1 was more prevalent than EBV type 2 in all nationalities (Table 9) 
 
4.6 EBV Strains by Sequencing of the LMP-1 gene 
Out of the 51 genotyped samples, 30 samples were selected used for further sub 
genotyping of EBV into different subgenotypes or strains. To do that, the C-terminus of 
the LMP-1 gene was amplified using nested PCR (see materials and method section, page 
32). The product of the second PCR round, which amplified a 587 bp fragment was 
cloned in the multiple cloning site of the pDrived cloning plasmid. Positive clones were 
tested for the presence of the cloned fragment using EcoRI restriction digestion (Figure 
16 and 17). Three to six clones from each samples (total of 119 clones) were sent to MC 
Lab for sequencing. 
The sequences of the EBV LMP1 gene were aligned and compared to the 
reference sequences of previously reported EBV strains: The prototype B95-8, Med+, 
Med- , China 1, China 2, Alaskan, NC, CAO and SEA 1 (CD+16). Molecular 
Phylogenetic analysis by Maximum Likelihood method was performed (Figure 18). 
Surprisingly, analysis revealed the dominance of CD+16, also known as  South Eastern 
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Asia 1 (SEA1) strain, which is a close derivative that belongs to China 1 strain. All of the 
sequenced clones 119/119 (100%) were carrying CD+16 (SEA1) strain. 
 
4.7 LMP-1 30 bp and 69 bp Deletions  
Due to high variability of the LMP-1 gene, mutational hot spots and deletions can 
be found. Therefore, we have examined the presence of two previously reported deletions 
(del- LMP1): 30 bp deletion, and a larger deletion of 69 bp in length. Our results shows 
that 3/30 (10%) of the samples had 30-bp deletion. In addition, 4/30 (13.3%) had the 69 
bp deletion. All of the aforementioned deletions were within EBV type 1 samples. No 
deletions were detected in the 5 sequenced samples that belong to EBV type 2 (Table 10). 
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Table 1. Demographic Characteristics of the Studied Subjects (N=673)  
 
 
 
 
 
 
 
 
 
 
 
 
 
Male 
Female
Qatari
Male 
Female
Non-Qatari
Male 
Female
<20-30
31-40
41-50
>50
Category No.(%)
Gender 
659 (97.9)
14 (2.1)
10 (2.2)
Age
176 (26.15)
264 (39.2)
174 (25.9)
59 (8.8)
Nationality
223 (33.1)
219 (98.2)
4 (1.8)
450 (66.9)
440 (97.8)
Qatari 
33% 
Non 
Qatari 
67% 
Nationality N=673 
Male 
98% 
Female 
2% 
 Gender N=673  
Figure 4. Gender distribution of the studied 
subjects. Total number =673 
Figure 5. Nationality distribution of the 
studied subjects. Total number = 673 
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Figure 6. Distribution of age groups in the studied population. Total number =673.  
Mean age =37.1, SD=9.4.  
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Figure 7. EBV seroprevalence in the studied subjects defined by a one or more positive 
reaction for EBV antibodies: VCA-IgG, VCA-IgM, EA-IgG, EBNA-IgG, and EBNA-
IgM. 
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Table 2. EBV seroprevalence in the studied population (N=673) 
 
 
 
 
 
Table 3. Seroprevalence of different EBV antibodies in the studied population (N=673) 
 
 
No. (%)
 Gender
Male 659
Female 14
 Nationality
Qatari 223
Male 219
Female 4
Non-Qatari 450
Male 440
Female 10
 Age Group
<20 - 30 176
31 - 40 264
41 - 50 174
> 51 59
 Category Total No.
No. (%)
EBV serology
P -ValuePositive Negative 
4 (100) 0 (0)
441 (98) 9 (2)
431 (97.9) 9 (2)
645 (97.9) 14 (2.1)
0.581
14 (100) 0 (0)
218 (97.8) 5 (2.2)
0.8358
214 (97.7) 5 (2.3)
0 (0)
10 (100) 0 (0)
169 (96) 7 (4)
0.037
257 (97.3) 7 (2.7)
174 (100) 0 (0)
59 (100)
 EBV antibody No of positive samples (%)
 VCA- IgM 12 (1.8)
 VCA- IgG 659 (97.9)
 EA - IgG 71 (10.6)
 EBNA - IgM 59 (8.8)
 EBNA - IgG 616 (91.5)
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Figure 8. Seroprevalence of EBV antibodies: EBNA-IgM, EBNA-IgG, EA-IgG, VCA-
IgM, and VCA-IgG, among the studied subjects. Detection of EBV antibodies in the 
plasma samples was performed by ELISA technique.  
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Figure 9. EBV presumed stage of infection according to the ELISA results. Serology 
patterns were classified into six possible EBV infection stages: Early infection (positive 
VCA-IgM and VCA-IgG), active infection (positive VCA-IgG, and EA-IgG, with or 
without VCA-IgM), reactivation (positive VCA-IgG, EBNA-IgG, and EA-IgG), recent 
active infection (positive VCA-IgM, VCA-IgG, EBNA-IgG). No infection (negative for 
all anti-EBV antibodies) 
 
2.10% 
0.60% 
0.89% 
0.74% 
85.97% 
9.70% 
EBV infection stage N= 673  
No infection
Early infection
Active infection
Recent active infection
Past infection
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Figure 10. EBV seroprevalence in different age groups tested by ELISA. Seroprevalence 
ranged from 96% in the youngest age group (<20-30 years), to 100% in the eldest age 
group (>51 years). 
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No. (% ) No. (% ) No. (% ) No. (% ) No. (% ) No. (% )
Gender
659
14
Nationality
223
450
Age Group
176
264
174
59
Total 673
Table 3. c  EBV infection status in the studied population (N=673)
Category Total No.
EBV serology 
Past infection Early infetion Active Infection Recent Active Reactive infection No infection
P-Value
572 (86.6) 3 (0.5) 6 (0.9) 5 (0.8) 59 (9) 14 (2.1)
<0.001
7 (50) 1 (7.1) 0 (0) 0 (0) 6 (42.9) 0 (0)
0.949
388 (86.2) 3 (0.7) 5 (1.1) 3 (0.7) 42 (9.3) 9 (2)
191 (85.7) 1 (0.4) 1 (0.4) 2 (0.9) 23 (10.3) 5 (2.2)
0.337
230 (87.1) 2 (0.8) 2 (0.8) 2 (0.8) 21 (8) 7 (2.7)
150 (86.2) 0 (0)
146 (83) 2 (1.1) 2 (1.1) 2 (1.1) 17 (9.7)
        Qatari
        Non-Qatari
2 (1.1) 0 (0) 22 (12.6) 0 (0)
53 (89.8) 0 (0) 0 (0) 1 (1.7) 5 (8.5) 0 (0)
7 (4)
         Male
         Female
         <20 - 30
         31 - 40
         41 - 50
          > 51
Table 4. EBV infection stage related to gender, nationality, and age group (N=673) 
 
 
 
 
 
 
  
 
 
 
 
 
    
  
 
51 
 
 
Table 5. EBV seroprevalence among major nationalities (N=673) 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No. (%) No. (%)
Qatar 223
Syria 95
Eygpt 92
India 59
Jordan/Palestine 61
Pakistan 20
Total 673
Category Total No.
EBV Serology 
P -ValuePositive Negative 
Nationality
218 (97.8) 5 (2.2)
0.4
92 (96.8) 3 (3.2)
92 (100) 0 (0)
58 (98.3) 1 (1.7)
58 (95.1) 3 (4.9)
20 (100) 0 (0)
Others 123 121 (98.4) 2 (1.6)
  
 
52 
 
Table 6.  EBV viremia rate among the studied subjects  (N=673) 
 
 
 
 
 
 
Table 7. EBV viremia rate among major nationalities (N=673) 
 
 
No. (%) No. (%)
 Gender
Male 659
Female 14
 Nationality
Qatari 223
Male 219
Female 4
Non-Qatari 450
Male 440
Female 10
 Age Group
<20 - 30 176
31 - 40 264
41 - 50 174
> 51 59 40 (67) 19 (32.2)
Category Total No.
213 (48.4)
4 (40) 6 (60)
79 (44.8) 97 (55.1)
0.007
134 (50.76) 130(49.2)
101 (58) 73 (41.9)
123 (55.2) 100 (44.8)
0.323
112 (51.1) 98 (44.7)
2 (50) 2 (50)
230 (51.1) 220 (48.9)
227 (51.6)
EBV DNA
P -ValuePositive Negative 
348 (52.8) 311 (47.2)
0.317
6 (42.9) 8 (57.1)
No. (%) No. (%)
Nationality
Qatar 223
Syria 95
Eygpt 92
India 59
Jordan/Palestine 61
Pakistan 20
Total 673
Others 123 59 (48)64 (52)
       Category Total No.
EBV DNA
P -ValuePositive Negative 
123 (55.2) 100 (44.8)
0.6
51 (53.7) 44 (46.3)
47 (51.1) 45 (48.9)
28 (47.5) 31 (52.5)
28 (45.9) 33 (54.1)
13 (65) 7 (35)
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Table 8. EBV viremia rate in different infection stages 
 
 
 
 
 
 
Positive
No. (%)
Negative 
No. (%)
No infection 14 0 (0) 14 (100)
Early infection 4 3 (75) 1 (25)
Active infection 6 6 (100) 0 (0)
Recent active infection 5 2 (40) 3 (60)
Past infection 579 304 (52.5) 275 (47.5)
Reactivation 65 39 (60) 26 (40)
Total 673 354 319
EBV detection by RT-PCR
Category by ELISA Total No P-value
<0.001
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Figure 11. EBV viremia rate in different infection stages. EBV DNA was detected using 
real time PCR for the DNA extracted from buffy coat. Serological patterns classified by 
serological testing of EBV antibodies using ELISA: Early infection (positive VCA-IgM 
and VCA-IgG), active infection (positive VCA-IgG, and EA-IgG, with or without VCA-
IgM), reactivation (positive VCA-IgG, EBNA-IgG, and EA-IgG), recent active infection 
(positive VCA-IgM, VCA-IgG, EBNA-IgG). No infection (negative for all anti-EBV 
antibodies). 
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Figure 12. Correlation between EBV presumed stage and EBV DNA viral load (in copies 
per µg of DNA). EBV viral load was quantified using quantitative real time PCR. 
Serological patterns were classified using ELISA testing. 
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Figure 13. The first round of PCR amplification for the EBNA2 gene using E2P1 and 
E2P2 primers that amplified almost the entire EBNA2 gen: 597 bp in length (Lane 1, 2 
and 3). Positive control: EBV positive samples. Negative control: sterile water. 
 
 
 
 
 
 
Figure 14. The second round of PCR amplification for the EBNA2 gene using EBV type 
1 specific primers (AP primers). Genotype 1 samples amplify a 497 bp fragment (Lane 
1,2, and 3). Sterile water was used as negative control. 
  
 
57 
 
 
 
Figure 15. The second round of PCR amplification for the EBNA2 gene using EBV type 
2 specific primers (BP primers). Genotype 2 samples amplified a 150 bp fragment (Lane 
1, and 5). Sterile water was used as negative control 
 
 
 
 
 
Table 9. Description of EBV genotypes (N=51) 
 
 
 
 
No. (%)
37/51 (72.5%)
10/14 (71.4)
27/37 (72.9)
12/51 (23.5 %) 
3/14 (21.4)
9/37 (24.3)
2/51 (3.9%)
1/14 (7.1)
1/37 (2.7)
            Qatari
            Non-Qatari
    Mixed Genotype 1 & 2
            Qatari
            Non-Qatari
No. of EBV genotyped samples  
    Genotype 1
            Qatari 
            Non-Qatari
    Genotype 2
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Figure 16. PCR amplification of the C- terminus of LMP-1 gene using primers that 
amplify a 587 bp fragment.  
 
 
 
 
 
Figure 17. EcoRI restriction digestion of the pDrive  cloning plasmids harboring the 
LMP-1 PCR fragment. The 587 bp cloned fragments (Lane 1-7) were dropped out after 
digestion of the pDrive plasmid (upper thick band) with EcoRI.  
 
 
 
  
 
59 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
\ 
 
 
 
 
Figure 18. Phylogenetic tree of LMP-1 gene sequences. Pair-wise distance differences 
analysis was used and reference sequences representing reported EBV strains were used 
for sequence homology comparison. Sequences were aligned and phylogenetic tree was 
generated using the neighbor joining method. 
SAE1 strain  
Accession no. from the  
GeneBank: AY493834 
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EBV genotype Total no. 30 bp deletion (%) 69 bp deletion (%) non deleted (%) p- value
 Type 1 25 3 (12) 4 (16) 18 (72)
Type 2 5 0 (0) 0 (0) 5 (100)
Total 30 3 (10) 4 (13.3) (23) 76.7
0.609
 
Table 10. Summary of Deleted and Non-Deleted Isolates (n=30) 
 
 
 
 
 
 
 
 
 
 
  
 
61 
 
5- DISCUSSION 
In this study, EBV seroprevalence among healthy blood donors was found to be 
97.9%, which is close to the EBV general seroprevalence rate around the world. 
Although socioeconomic factors contribute to the age of EBV seroconversion, yet, in 
adulthood, 90 to 99% of individuals, are usually EBV seropositive (17, 57). According to 
the CDC estimates, 95% of adults at age between 35 and 40 years age have been 
previously exposed to EBV infection (56). Our results also show that there is a significant 
association between EBV seroprevalence and age. In this study, seroprevalence increased 
with age until it reached to 100% prevalence in the group of the participants aged 40 
years or older. Similar findings were reported in a study that investigated the 
seroprevalence of EBV in different age groups in Thailand, as EBV seroprevalence 
increased with age and all individuals are EBV seropositive at age of 40 years (114). In 
another study conducted in US to estimate EBV seroprevalence among organ donors, it 
revealed that 94% of donors were seropositive and higher percentage of EBV 
seronegative donors was observed in the young age groups (115).  
When we investigated the association between EBV seroprevalence and 
nationality, as expected, there was no significant difference. All nationality groups had 
close prevalence rates. EBV seropositivity can be affected by socioeconomic factors, 
which vary between different geographic areas. However, at adulthood, more than 90% 
of people are seropositive (5, 114). As all our studied subjects are adult blood donors 
with a minimum age of 19 years, no significant difference in the rate of infection was 
found between different nationalities. 
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Although the indirect immunofluorescence assay (IFA) is considered the gold 
standard for EBV immune-diagnosis, enzyme immunoassay (EIA) is the routine 
diagnostic technique used because of its high throughput (78). Compared to other 
techniques, serological testing is still preferable and commonly used although it shows 
high degree of variability (73). Detection of EBV antibodies in the serum of patients can 
help to identify the stage of infection, but can also mislead the diagnosis or produce false 
results.  
EBNA-1 antibodies are usually used to identify past infection as they appear late 
in the stage of infection, however, in our study, 6.7 % of the donors with past infection 
had negative result for EBNA-1 antibodies, although they are positive for VCA-IgG.  
Previous reports have also revealed that 5 to 10% of healthy people never develop 
EBNA-1 antibodies (76). Moreover, in immunosuppression, loss of anti EBNA-1 is 
frequently seen (85). As reported by others (84), our results confirm that the use VCA-
IgG is superior to EBNA-1 IgG to indicate prior exposure to EBV, as VCA-IgG was 
found in all EBV seropositive individuals. Balfour et. al. reported that measuring VCA- 
IgG antibodies is found to be best single test to indicate a previous EBV infection (84).  
Furthermore, EA- IgG is usually undetected after convalescence. When EA- IgG 
is detected, it might indicate reactivation of the virus (90). However, reactivation can’t be 
confirmed by only the presence of EA-IgG. That is,  several studies have shown that 
approximately 20% of previously infected individuals retain a positive EA-IgG for years 
(76). Among our tested samples, 65 (9.7%) have positive EA-IgG, and therefore, were 
classified under EBV reactivation category. Yet, even though EBV reactivation is not 
rare among healthy individuals and it can occur periodically, these findings need to be 
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supported by other tests, and by the clinical picture of the patient/donors to confirm a past 
infection with persistent EA-IgG.  
Detection of EBV DNA revealed that 52.6% of our studied subjects carry EBV 
DNA in their peripheral blood mononuclear cells (PMNCs). Previous studies have also 
investigated EBV viremia among healthy subjects. Hudnall et. al reported high rate of 
EBV viremia among healthy blood donors. They found that 72% of 100 randomly 
selected donors have detectible EBV in their white blood cells (58). In another study with 
larger samples, Nishiwaki et. al reported that out of 953 healthy individuals, 39.5 % had 
EBV viremia in their PMNCs (59). A lower rate (5.1% of 198 tested samples) was 
reported in similar study that investigated the presence of EBV DNA in healthy 
individuals (60). However, in the latter study, the type of sample that was used for EBV 
detection was not indicated. EBV detection by PCR is highly affected by the specimen 
used, and the variation in sample types must always be considered when comparing 
different studies. Usually healthy individuals don’t carry EBV in their cell free proportion 
of blood. Studies that detected EBV in serum of healthy individuals reported very low or 
undetected EBV viremia (97, 100, 106).  
Since detection of EBV DNA is considered a reliable method, which 
complements serology testing, and aids in diagnosing acute infection and confirming 
silent reactivation (50, 77, 100, 101). We investigated the correlation of EBV DNA 
presence and ELISA results. We also investigated the correlation of ELISA results with 
EBV viral load. For the EBV seronegative group, our PCR results were well-matched 
with the serology results. All donors classified by ELISA as EBV negative showed 
undetectable EBV DNA by PCR. Similarly, all samples with a serological pattern of 
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EBV active infection carried amplifiable quantity of EBV DNA. However, discrepancies 
between serology and PCR were found in early infection, reactivation, and recent active 
infection groups.  
In the group of EBV early infection, with positive VCA-IgM and VCA-IgG 
antibodies, 3 out of 4 samples showed positive PCR results, while one sample was PCR 
negative. The reason behind this could be false positive ELISA results, or the amount of 
EBV was below detection limit. Previous studies showed that circulating EBV DNA 
levels in whole blood or plasma increases during the first two weeks on infection, then 
declines to low or undetectable levels after several weeks to months (40). Interestingly, 
kinetics of EBV differs from person to person, and different levels are reached before the 
it became stable (116).  
In EBV recent active infection group, PCR results were also not consistent with 
the serology results. This category is defined by positive antibodies against VCA-IgM, 
VCA-IgG and EBNA-IgG. However, we believe that PCR results are more reliable, due 
to the high rate of false positive results in VCA-IgM immunoassays (82, 83). Cross-
reactivity of VCA-IgM determined was reported with other antigenically related 
infections, especially with CMV infection (82, 83). Moreover, the specificity of the 
ELISA kit we used is 93.2% as stated by the manufacturer. This indicates the possibility 
of having false positive results.  
In samples classified with EBV reactivation, 60% were PCR positive. EBV 
reactivation was identified by the presence of past infection antibodies VCA-IgG and 
EBNA1-IgG, with detectable EA-IgG again. However, EA-IgG persists for life in around 
20% of individuals (73, 76). Hence, based on serology only, reactivation can’t be 
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confirmed, and it can’t predict the exact reactivation time (50). EBV DNA detection and 
viral load quantification is used to assist in the diagnosis of EBV reactivation, yet, 
discrepancies can be found between PCR and serology. In a study that investigated EBV 
reactivation in healthy carriers, Maurmann et. al reported that EBV viremia and viral load 
changes happen more frequently in contrast with the serological profile. Further, this 
could be explained due to the low sensitivity of serological assays (50).  
In our study, comparison of EBV viral load in different EBV stages showed that 
there is no significant difference among those different groups. High viral load were 
expected to be found in reactivation or acute infection, but there was no significant 
difference. This could be explained by the difference in sample size in each group. 
Samples with active infection or reactivation were much less than past infection samples. 
This didn’t allow for a valid comparison in EBV viral load. Moreover, our study is cross 
sectional, we tested only one sample for each donor, and we didn’t follow up or test more 
samples for each individual in different time periods. Hence, a phase of EBV viremia or 
viral load increase is possible to be missed.  
In the present study, EBV genotyping revealed predominance of genotype 1, 
which was found in 72.5% of 51 genotyped individuals. This genotype is usually more 
prevalent in Europe, America, China, and South Asia (5, 55). On the other hand, EBV 
type 2 was detected only in 23.5% of samples. EBV type 2 is less prevalent in the 
aforementioned populations and is more observed in African and Papua New Guinean 
populations. (5, 55). Recent study investigated that prevalence of EBV genotypes in 
different ethnic groups in  Polish, Taiwanese and Arabic individuals. Results revealed 
that in both Polish and Taiwanese, EBV type 1 was more prevalent, it was identified in 
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81.8% cases, while type 2 was found in 18.2% cases. Mixed infection with both 
genotypes was found only in one on the two Arabic participants (33). In our study, mixed 
infection was also detected with low prevalence. Only 2/51 (3.9%) had both types of 
EBV. Previous studies also have reported that healthy individuals can acquire a mixed 
EBV infection (9, 117). As reported by others, because of mixed infection, it could be 
concluded that the one genotype does not provide immunity against the other genotype.      
In investigating the subtypes of EBV, sequencing of the LMP-1 gene revealed 
that all our samples have SEA1 strain. This strain was previously reported in a study that 
identifies EBV strains in healthy and diseased individuals in Southern Thailand. Saechan 
et al. reported that EBV SEA1 strain was found in 1 out of 18 tested healthy individuals 
(11). However, to our knowledge there are no previous studies that investigated the 
circulating EBV strains among Qatari or other Arabic neighboring countries, and this is 
the first study to report the EBV LMP-1 strains among healthy individuals.  
Deletions in the LMP-1 gene was correlated to the prognosis of EBV associated 
diseases, and some are reported in healthy individuals in previous studies (31, 33, 118). 
We have found that 12% of our sequenced subjects had a 30 bp deletion. Moreover, 4% 
had a 69 bp deletion. Our findings are supported by other studies from different 
populations. LMP-1 30 bp deletion was reported in healthy Polish and Taiwanese carriers  
in a recent study by Polz et al. (33). In another study investigated LMP-1 deletions 
among Moroccan patients compared to healthy individuals, they reported that about 14% 
of their healthy donors carry the 69 bp deletion, and 36% carried 30 bp deletion (119) 
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Study Limitations 
This study was applicable for investigating EBV seroprevalence, genotypes, and 
sub genotypes among healthy individual with different nationalities and age groups. 
However, there are some limitations. For instance, in regard to gender, we couldn’t have 
a valid comparison because of the large difference between female number (n=14) and 
males (n=659). Further, although statistical analysis revealed a significant difference in 
stage of infection between males and females, this significance could be considered 
invalid and can’t be generalized. The number of donor males is usually higher than 
females, however, increasing the sample size can increase the number of females and 
allow for a better comparison.  Moreover, our samples were collected from the donor 
unit, and the minimum age of blood donation is 18. The majority of our studied samples 
were between 31-40 years old, and no participants were below the age of 19. In order to 
study EBV seroconversion and investigate the best age of vaccine administration, it is 
important to include younger age groups.  
Serological testing for approximately 700 sample was in fact time consuming, 
because each sample was tested for 5 different EBV antibodies. As a result, for all 
samples, a total of more than 3500 ELISA tests were performed. Despite the time and 
cost spent on these tests, not all samples were included in the analysis. Our sample size 
was corrected to 673, due to the lack of some important demographic data that we 
couldn’t obtain from the donor unit.  
VCA-IgG Avidity assay was to be performed to confirm ELISA classification in 
acute infection samples, especially for those with inconsistent ELISA and PCR results. 
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But due to the time limitation of this study and unavailability of the confirmation tests, 
this assay was not included in the current results, but will be performed in the near future.  
 
Future Work 
 Performing VCA-IgG avidity assay to confirm the ELISA results and to solve the 
inconclusive findings in comparison with PCR results 
 As our participants are all healthy individuals, we used the cells proportion of the 
blood to detect and measure EBV viremia. Measuring EBV viral load in the 
plasma of acute infection donors, will aid also in the confirmation of acute 
infection. 
 Cloning and sequencing for more samples to confirm our genotyping findings and 
also to study EBV strain variation in a larger sample size.  
 We have performed our EBV strain variation analysis on the DNA level. We 
compared the nucleotide sequence with the previously reported sequences. In the 
future, translation of the sequenced clones will be performed, in order to study the 
changes in amino acid. That is, performing genotyping based on amino acid 
sequence could revealed more accurate results and findings of other circulating 
sub genotypes in this part of the world.    
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6- CONCLUSION 
EBV is a highly prevalent infection, affecting more than 90% of world’s 
population. Many studies have been done to estimate the rate of EBV seroprevalence. 
However, national reports in Qatar that estimate EBV prevalence are not available, and to 
our knowledge, this study represents the first estimate of EBV in Qatar.  
We have shown than EBV seroprevalence is 97.89%, and viremia rate is 52.6%, 
both significantly increase with age. EBV Genotype 1 and Subtype SEA1 are the 
predominating (72.5%, 100%, respectively) in Qatar. Moreover, LMP-1 30 bp and 69 bp 
deletions were found in 10% and 13.3%, respectively. This study should provide the 
epidemiologists, blood banks’ personnel, researchers and clinicians with EBV prevalence 
estimates and molecular epidemiology of EBV as a highly prevalent transfusion 
transmissible oncovirus. 
Estimates of EBV infection are important to give researchers and clinicians 
correct data about how many people are affected, and to identify people at high risk 
groups such as pediatrics and immunocompromised patients. Also, it aids to ensure that 
safety health practices are followed to eliminate the EBV spread, especially in blood 
banks, and organ transplantation centers where EBV constitute a life threating risk to 
recipients. Moreover, EBV estimates in relation to age are highly needed to help in 
identifying the right age to introduce EBV vaccine in the future.  
As an oncovirus with a complex cancer related etiology and high molecular  
variability, it is important to know what is the molecular epidemiology of EBV in this 
specific area and to identify the circulating EBV strains among the population.  Finally, 
we believe that more studies should be conducted in this region to compare the EBV 
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strains between healthy carriers and patients with EBV associated diseases or 
malignancies. 
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